Because cancer cells harbor significantly higher misfolded proteins than normal cells, targeting DYRK2 could indeed tip the scales for proteostasis in malignant cells and provide a significant therapeutic window for targeting specific cancers. The gene discussed is DYRK2; the disease is cancer.